Loading...
XNAS
PPBT
Market cap6mUSD
Jul 11, Last price  
2.40USD
1D
-4.76%
1Q
-4.00%
Jan 2017
-99.61%
Name

Purple Biotech Ltd

Chart & Performance

D1W1MN
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
78.04%
Rev. gr., 5y
115.44%
Revenues
0k
00000901,0001,000,0001,000,0001,000,000-320,000-910,00000
Net income
-7m
L-63.58%
-703-2,628,000-5,252,000-4,202,000-12,125,000-12,272,000-5,200,000-6,109,000-12,405,000-18,463,000-20,825,000-19,880,000-7,240,000
CFO
-14m
L-25.27%
-253-512,000-4,526,000-3,308,000-6,262,000-8,627,000-8,480,000-5,581,000-12,092,000-15,071,000-16,735,000-19,226,000-14,367,000
Earnings
Aug 14, 2025

Profile

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug for cancer patients in the United States. Its oncology pipeline includes CM24, a monoclonal antibody that blocks carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer and pancreatic cancer; and NT219, a small molecule that targets insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment of recurrent and/or metastatic solid tumors and squamous cell carcinoma of the head and neck cancer. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.
URL
https://purple-biotech.com/
IPO date
Sep 03, 1978
Employees
20
Domiciled in
IL
Incorporated in
IL

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
(910)
184.38%
Cost of revenue
10,555
17,230
22,804
Unusual Expense (Income)
NOPBT
(10,555)
(17,230)
(23,714)
NOPBT Margin
2,605.93%
Operating Taxes
(935)
Tax Rate
NOPAT
(10,555)
(17,230)
(22,779)
Net income
(7,240)
-63.58%
(19,880)
-4.54%
(20,825)
12.79%
Dividends
Dividend yield
Proceeds from repurchase of equity
5,809
1,563
1,498
BB yield
-3.57%
-0.05%
-0.29%
Debt
Debt current
183
188
194
Long-term debt
183
514
836
Deferred revenue
Other long-term liabilities
140
2,659
145
Net debt
(8,158)
(14,710)
(31,083)
Cash flow
Cash from operating activities
(14,367)
(19,226)
(16,735)
CAPEX
(228)
Cash from investing activities
509
13,881
19,914
Cash from financing activities
6,774
5,449
1,114
FCF
(10,373)
(17,018)
(22,565)
Balance
Cash
8,524
15,412
32,113
Long term investments
Excess cash
8,524
15,412
32,158
Stockholders' equity
(144,740)
(98,887)
(107,328)
Invested Capital
177,974
136,194
155,086
ROIC
ROCE
EV
Common stock shares outstanding
34,651
221,332
18,482
Price
4.69
-69.94%
15.60
-43.48%
27.60
-64.52%
Market cap
162,515
-95.29%
3,452,779
576.90%
510,090
-63.17%
EV
154,408
3,438,159
479,194
EBITDA
(10,369)
(17,033)
(23,513)
EV/EBITDA
Interest
41
2,182
126
Interest/NOPBT